Quantum Genesis AI Corp. Reports Reduced Net Loss and No Revenue for Quarter Ending April 30, 2026

Quantum Genesis AI Corp., formerly known as Quantumzyme Corp., reported its financial results for the quarter ending April 30, 2026, revealing a net loss of $24,912, a significant reduction from the $65,763 loss recorded in the same quarter of the previous year. For the nine months ending April 30, 2026, the company experienced a net loss of $4,404,437, compared to a loss of $161,092 for the same period in 2025. The company did not generate any revenue during these periods, maintaining a consistent trend from the previous fiscal year.

Operating expenses for the quarter decreased to $19,083 from $60,453 year-over-year, primarily due to reduced professional fees. For the nine-month period, operating expenses also fell to $59,661 from $145,921, reflecting a similar trend. The company noted that while expenses have decreased, it anticipates an increase in future operating costs as it ramps up activities under its business model. Other expenses for the nine months included a significant loss on the settlement of debt amounting to $4,325,872, which contributed to the overall net loss.

In terms of strategic developments, Quantum Genesis AI Corp. underwent a name change and a significant organizational shift in early 2023, acquiring assets related to enzyme catalyst technologies. This acquisition was formalized through an Asset Purchase Agreement, which included proprietary intellectual property. The company has also issued shares to settle debts, including 2,010,000 shares valued at $4,401,900 to address outstanding notes payable and accrued interest. As of April 30, 2026, the company had total current assets of $59 and total current liabilities of $443,313, resulting in a working capital deficit of $443,254.

The company’s operational metrics indicate a challenging financial landscape, with no revenue generation and a reliance on external funding to sustain operations. As of the reporting date, Quantum Genesis AI Corp. had a total of 40,972,050 shares outstanding, an increase from 38,962,050 shares in the previous year. The company continues to face substantial doubt regarding its ability to continue as a going concern, emphasizing the need for additional funding through securities sales or private investments.

Looking ahead, Quantum Genesis AI Corp. acknowledges the uncertainties surrounding its financial future, particularly in securing necessary funding to support its operations and growth plans. The company has not established firm agreements for financing and recognizes that failure to obtain sufficient funds could severely restrict its operational capabilities and development plans. The management remains focused on maintaining financial flexibility to meet project commitments and pursue expansion objectives.